Table 1.
Characteristics of kidney transplant recipients (n=2,336). P-value for comparisons between recipients with CGD and without CGD.
| Characteristic | All n= 2,336 | No CGD n = 1,970 | CGD n= 366 | p-value |
|---|---|---|---|---|
| 0.21 | ||||
| Ethnicity: White | 75 % | 76 % | 72 % | |
| Black | 19 % | 19 % | 20 % | |
| Asian | 3 % | 3 % | 3 % | |
| Other | 2 % | 2 % | 4 % | |
| Not Known | <1 % | < 1% | < 1% | |
| Hispanic | 2 % | 1 % | 2% | 0.25 |
| Male | 63 (%) | 63 % | 61 % | 0.32 |
| Mean age at enrollment in years | 49 ±14 | 50 ±14 | 46 ±16 | < 0.001 |
| Cause of End Stage Kidney Disease: | 0.03 | |||
| Diabetes | 28 % | 27% | 31% | |
| Glomerular disease | 21 % | 20% | 25% | |
| HTN | 14 % | 15% | 11% | |
| Polycystic kidney disease | 13 % | 13% | 10% | |
| Other | 21 % | 21% | 21% | |
| Unknown | 3 % | 4% | 2% | |
| History of diabetes | 36% | 36% | 38% | 0.37 |
| Living donor transplant | 58 % | 58% | 58% | 0.95 |
| Mean donor age in years | 40 ±14 | 40±14 | 43±14 | <0.01 |
| Male donor* | 48 % | 48% | 49% | 0.3 |
| Cold Ischemia time >24 h* | 8 % | 8% | 8% | 0.74 |
| Prior kidney Transplant | 13 % | 13% | 15% | 0.3 |
| Need for dialysis in the first 14 days post transplant* | 10% | 9% | 14% | 0.005 |
| Final PRA present * | 42% | 42% | 43% | 0.82 |
| T or B Crossmatch positive* | 6 % | 5% | 8% | 0.11 |
| Plasmapheresis prior to transplants | 3 % | 2% | 5% | 0.01 |
| Zero HLA mismatches | 12 % | 13% | 9% | 0.065 |
| Antibody Induction: | <0.0001 | |||
| Monoclonal | 44 % | 46% | 35% | |
| None | 4 % | 4% | 2% | |
| Other | 3 % | 2% | 5% | |
| Polyclonal | 50 % | 48% | 58% | |
| Smoking status:* | ||||
| Never | 58 % | 58% | 58% | 0.03 |
| Past | 32 % | 33% | 29% | |
| Current | 9 % | 9% | 13% | |
| Pre-emptive transplant | 29 % | 29% | 27% | |
| Steroid withdrawal by day 14 post-transplant | 39 % | 38% | 42% | 0.53 |
| Use of Mycophenolate Mofetil | 99% | 99% | 99% | |
| CNI type: | 0.17 | |||
| Cyclosporine | 28 % | 26% | 38% | 0.79 |
| Tacrolimus | 69 % | 71% | 59% | <0.0001 |
| None | 3 % | 3% | 3% | |
| SPK** | 6 % | 5% | 7% | |
| Prior Non-kidney Transplants* | 10 % | 9% | 13% | 0.22 |
| CMV Recipient/Donor Status* | 0.06 | |||
| Recipient (−)/Donor (−) | 20 % | 20% | 21% | <0.01 |
| Recipient (+) | 63 % | 64% | 56% | |
| Recipient (−)/Donor (+) | 17 % | 16% | 23% | |
| Acute Rejection in first 3 months post-transplant | 9 % | 8% | 13% | |
| <0.01 |
*
Missing data: Living donor gender missing in 7 subjects, need for dialysis in the first 14 days post-transplant missing in 4 subjects, Cold Ischemia time missing in 209 subjects, Final PRA missing in 7 subjects, Plasmapheresis prior to transplant missing in 57 subjects, B/T cell crossmatch missing in 51 subjects, Smoking status missing in 7 subject, Use of Mycophenolate Mofetil and CNI type was missing in 215 subjects, Prior non-kidney transplant missing in 44 subjects, CMV recipient/donor status missing in 44 subjects.
**
SPK= Simultaneous kidney pancreas transplants